| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2849921 | American Heart Journal | 2008 | 9 Pages |
Abstract
Length of stay is the determinant of cost for HF hospitalizations. Use of vasoactive therapy is a marker for longer LOS, higher mortality, and greater costs. Improved reimbursement rates or improved therapeutic options that lessen LOS are required if the costs of HF care are to be minimized.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Paul J. MD, Jason MPH, Thomas E. PhD, Mark A. PhD,